Annamaria Bianco
Research Subjects
Annamaria Bianco has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Marco O. Bertelli
CREA (Research and Clinical Centre), Fondazione San Sebastiano, Misericordia di Firenze
14 shared publications - Daniela Scuticchio
CREA (Research and Clinical Centre), Fondazione San Sebastiano, Misericordia di Firenze
4 shared publications Elisabetta Filomena Buonaguro
Reproductive Science, and Odontostomatology, University of Naples Federico II
3 shared publications- Luciana Forte
CREA (Research and Clinical Centre), Fondazione San Sebastiano, Misericordia di Firenze
3 shared publications - Eddie Chaplin
London South Bank University
2 shared publications Elisa Rondini
CREA (Research and Clinical Centre), Fondazione San Sebastiano, Misericordia di Firenze
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by MDPI AG in Preprints.org
Deprescribing Antipsychotics Through Integrated Behavioral Treatment in an Adult with Intellectual Disability and Severe Challenging Behavior: A Case Report
Background: Psychotropic medications are frequently prescribed off-label in individuals with intellectual disability (ID) and other neurodevelopmental disorders to manage challenging behaviors (CBs), often in the absence of a clearly defined psychiatric condition. Although antipsychotics and benzodiazepines may reduce acute behavioral dysregulation, long-term use is associated with significant adverse effects and may contribute to functional suppression rather than adaptive regulation. Increasing attention has therefore been directed toward integrated treatment models combining behavioral interventions with systematic psychopharmacological review and deprescribing strategies. Case presentation: We report the case of a 26-year-old woman with ID, severe CBs, and a history of long-term psychotropic polypharmacy admitted to a high-intensity behavioral residential care setting. At admission, the patient presented with severe aggression, self-injurious behavior, property destruction, mutism, psychomotor slowing, and marked social disengagement while receiving haloperidol, diazepam, and valproate. A multidisciplinary intervention based on Applied Behavior Analysis (ABA) and functional assessment was implemented within a “Tandem Treatment” framework integrating behavioral intervention with gradual psychotropic deprescribing. Behavioral procedures included functional communication training, differential reinforcement, environmental modulation, and structured skill acquisition programs. Over the course of treatment, antipsychotic medication was discontinued and benzodiazepines were progressively reduced without behavioral deterioration or rebound phenomena. Concurrently, severe challenging behaviors showed a marked and sustained reduction, while adaptive functioning, participation in daily activities, sleep regulation, social responsiveness, and quality-of-life indicators improved substantially. Conclusions: This case suggests that, in selected individuals with ID and severe CBs, integrated behavioral treatment may support the safe reduction of psychotropic medications while improving adaptive and clinical outcomes. The findings highlight the importance of function-based behavioral assessment, multidisciplinary coordination, and data-driven psychopharmacological monitoring in the management of complex neurodevelopmental conditions. Further controlled studies are needed to clarify the role of integrated deprescribing models in this population.
- 4 August 2026
- Published by MDPI AG in Preprints.org
Open AccessDeprescribing Antipsychotics Through Integrated Behavioral Treatment in an Adult with Intellectual Disability and Severe Challenging Behavior: A Case Report
Background: Psychotropic medications are frequently prescribed off-label in individuals with intellectual disability (ID) and other neurodevelopmental disorders to manage challenging behaviors (CBs), often in the absence of a clearly defined psychiatric condition. Although antipsychotics and benzodiazepines may reduce acute behavioral dysregulation, long-term use is associated with significant adverse effects and may contribute to functional suppression rather than adaptive regulation. Increasing attention has therefore been directed toward integrated treatment models combining behavioral interventions with systematic psychopharmacological review and deprescribing strategies. Case presentation: We report the case of a 26-year-old woman with ID, severe CBs, and a history of long-term psychotropic polypharmacy admitted to a high-intensity behavioral residential care setting. At admission, the patient presented with severe aggression, self-injurious behavior, property destruction, mutism, psychomotor slowing, and marked social disengagement while receiving haloperidol, diazepam, and valproate. A multidisciplinary intervention based on Applied Behavior Analysis (ABA) and functional assessment was implemented within a “Tandem Treatment” framework integrating behavioral intervention with gradual psychotropic deprescribing. Behavioral procedures included functional communication training, differential reinforcement, environmental modulation, and structured skill acquisition programs. Over the course of treatment, antipsychotic medication was discontinued and benzodiazepines were progressively reduced without behavioral deterioration or rebound phenomena. Concurrently, severe challenging behaviors showed a marked and sustained reduction, while adaptive functioning, participation in daily activities, sleep regulation, social responsiveness, and quality-of-life indicators improved substantially. Conclusions: This case suggests that, in selected individuals with ID and severe CBs, integrated behavioral treatment may support the safe reduction of psychotropic medications while improving adaptive and clinical outcomes. The findings highlight the importance of function-based behavioral assessment, multidisciplinary coordination, and data-driven psychopharmacological monitoring in the management of complex neurodevelopmental conditions. Further controlled studies are needed to clarify the role of integrated deprescribing models in this population.
- 9 July 2026
- Published by Springer Nature
- p. 4191-4203
Psychopathology in Persons with Intellectual Disability and Autism Spectrum Disorder
- 9 July 2026
- Published by Springer Nature
- p. 4191-4203
Psychopathology in Persons with Intellectual Disability and Autism Spectrum Disorder
- 9 July 2026
- Published by Springer Nature
- p. 1294-1308
Definition, Diagnosis, and Prevalence of Autism Spectrum Disorder
- 9 July 2026
- Published by Springer Nature
- p. 1294-1308
Definition, Diagnosis, and Prevalence of Autism Spectrum Disorder
- 9 July 2026
- Published by Springer Nature
- p. 3676-3692
Outcome Measures and Quality of Life in Neurodevelopmental Disabilities
- 9 July 2026
- Published by Springer Nature
- p. 3676-3692
Outcome Measures and Quality of Life in Neurodevelopmental Disabilities
- Open Access
- 17 October 2025
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 166, 105130
Portuguese validation of the Italian BASIQ quality of life assessment battery and implications for health resource consumption
- 17 October 2025
- Published by Elsevier in Research in Developmental Disabilities
- Vol. 166, 105130
Open AccessPortuguese validation of the Italian BASIQ quality of life assessment battery and implications for health resource consumption
- 9 May 2025
- Published by Springer Nature
- p. 1-15
Definition, Diagnosis, and Prevalence of Autism Spectrum Disorder
- 9 May 2025
- Published by Springer Nature
- p. 1-15
Definition, Diagnosis, and Prevalence of Autism Spectrum Disorder
- Open Access
- 18 March 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (3) , 316
Personal Quality of Life as an Outcome Measure of Antipsychotic Drug Management of Problem Behaviours in Adults with Intellectual Developmental Disorders with or Without Autism Spectrum Disorder
Background/Objectives: First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are frequently prescribed for the management of problem behaviours (PBs) in people with intellectual developmental disorders (IDDs) with or without autism spectrum disorder (ASD). However, the different effectiveness of these two groups of drugs has not been adequately investigated, especially in terms of person-centred outcomes, such as quality of life (QoL). The aim of the present observational study was to compare the personal QoL of two groups of people with IDDs with and without ASD, attending the same residential facility, but receiving FGAs and SGAs, respectively, for the management of PBs. Methods: Twenty-two people with IDDs (ten with ASD) receiving FGAs and twenty-three (eleven with ASD) receiving SGAs for the management of PBs were consecutively recruited. The participants underwent a complex clinical and instrumental evaluation, including the systematic psychopathological assessment for persons with intellectual and developmental disabilities—general screening (SPAIDD-G), the Wing’s handicaps, behaviours, and skills schedule (HBS), the DOTES, and the BASIQ (QoL Assessment tool battery). Follow-up evaluations were carried out after 6, 12, and 18 months. Results: The use of antipsychotics was withdrawn only in 16 cases, of which only 4 were for significant improvement. Treatment with FGAs was associated with more frequent discontinuation, a higher incidence of side effects, and a trend toward a lower efficacy on PBs than treatment with SGAs. FGAs also improved generic QoL significantly less than SGAs. Conclusions: The present pilot study is the first to compare FGAs and SGAs with respect to the generic QoL in people with IDDs and PBs. SGAs resulted to have a significantly greater positive impact on QoL than FGAs, despite demonstrating similar efficacy in treating PBs.
- 18 March 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (3) , 316
Open AccessPersonal Quality of Life as an Outcome Measure of Antipsychotic Drug Management of Problem Behaviours in Adults with Intellectual Developmental Disorders with or Without Autism Spectrum Disorder
Background/Objectives: First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are frequently prescribed for the management of problem behaviours (PBs) in people with intellectual developmental disorders (IDDs) with or without autism spectrum disorder (ASD). However, the different effectiveness of these two groups of drugs has not been adequately investigated, especially in terms of person-centred outcomes, such as quality of life (QoL). The aim of the present observational study was to compare the personal QoL of two groups of people with IDDs with and without ASD, attending the same residential facility, but receiving FGAs and SGAs, respectively, for the management of PBs. Methods: Twenty-two people with IDDs (ten with ASD) receiving FGAs and twenty-three (eleven with ASD) receiving SGAs for the management of PBs were consecutively recruited. The participants underwent a complex clinical and instrumental evaluation, including the systematic psychopathological assessment for persons with intellectual and developmental disabilities—general screening (SPAIDD-G), the Wing’s handicaps, behaviours, and skills schedule (HBS), the DOTES, and the BASIQ (QoL Assessment tool battery). Follow-up evaluations were carried out after 6, 12, and 18 months. Results: The use of antipsychotics was withdrawn only in 16 cases, of which only 4 were for significant improvement. Treatment with FGAs was associated with more frequent discontinuation, a higher incidence of side effects, and a trend toward a lower efficacy on PBs than treatment with SGAs. FGAs also improved generic QoL significantly less than SGAs. Conclusions: The present pilot study is the first to compare FGAs and SGAs with respect to the generic QoL in people with IDDs and PBs. SGAs resulted to have a significantly greater positive impact on QoL than FGAs, despite demonstrating similar efficacy in treating PBs.
- 12 May 2022
- Published by Springer Nature
- p. 707-718
Sexual Dysfunctions
- 12 May 2022
- Published by Springer Nature
- p. 685-706
Sleep Disorders/Sleep-Wake Disorders